Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors to be presented Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, ...

Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors to be presentedData supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, d ...

Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platformBASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- ...

Spanish biotech Reveal Genomics has formed a strategic partnership with oncology firm Ona Therapeutics to support the clinical development of ONA-255, a novel antibody-drug conjugate designed to ...

The immunotherapy OST-HER2 combined with palliative radiation has shown positive data in preventing or delaying amputation ...

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is ...

Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.

Reveal Genomics and Ona Therapeutics have entered a strategic partnership to expedite the clinical development of ONA-255.

Research doesn't happen by accident. Clinical trials don't appear overnight. Every treatment we use at the bedside starts with years -- often decades -- of basic science, drug development, trial ...

As global trade tensions escalate, Asian markets have faced significant volatility, with investors closely monitoring the economic impacts of ongoing tariff disputes. Amidst this uncertainty, ...